November 2, 2022 NurExone Announces Plan to Submit Pre-Investigational New Drug Meeting Request to U.S. Food and Drug Administration Read More
October 26, 2022 NurExone Announces Productivity and Quality Pilot Results of Patent-Pending Process for 3D Scaled Up Exosome Production Read More
October 12, 2022 NurExone Signs Letter of Intent with Nanometrix For its Exosome and Cargo Molecular Profiling AI-Driven Technology Read More
October 4, 2022 NurExone Announces Scientific Survey Results of Proprietary Exosome-based Technology Read More
September 7, 2022 NurExone Announces Letter of Intent for International Strategic Collaboration with denovoMATRIX Towards Large-Scale Exosome Production Read More
September 1, 2022 NurExone Announces Securities Issuing at Premium over Current Share Price to Settle EnerSpar’s Debts Prior to RTO Transaction Read More
August 26, 2022 NurExone Reports Second Quarter 2022 Financial Results and Provides Business Update Read More
August 9, 2022 James Richardson, the Former CEO of EnerSpar, Updates Shareholders After the Completion of RTO with NurExone Biologic Read More
July 19, 2022 NurExone Exosomes to Be Used in Cutting Edge Molecular Research at Hebrew University’s Burstyn-Cohen Lab Read More
July 11, 2022 NurExone to Collaborate with Polyrizon for Intranasal Administration of Cutting-Edge Exosome-Therapy Read More
June 22, 2022 NurExone Biologic Inc. to Begin Trading on TSX Venture Exchange and Retains Market Maker Read More
June 16, 2022 NurExone Biologic Inc. (Formerly, Enerspar Corp.) Announces Completion of Reverse Takeover Transaction Read More
May 18, 2022 EnerSpar and NurExone Announce Conditional Acceptance of Proposed Reverse Takeover Transaction Read More
March 15, 2022 EnerSpar and Israeli-Based Nurexone Provide Update on Progress to Closing RTO Read More
August 30, 2021 EnerSpar and Israeli-Based Nurexone Announce RTO and New NI 43-101 Filed by EnerSpar Read More
